ACCELERON PHARMA INC.

(XLRN)
End-of-day quote Nasdaq  -  11-18
178.75 USD   -0.52%
2021GLOBAL MARKETS LIVE : Airbus, BP, Merck, Pfizer, Meta...
2021Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
DJ
2021ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Biotechnology Index
CI
SummaryQuotesChartsNewsRatingsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about ACCELERON PHARMA INC.
2021GLOBAL MARKETS LIVE : Airbus, BP, Merck, Pfizer, Meta...
2021Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
DJ
2021ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Biotechnology Index
CI
2021ACCELERON PHARMA : Completion of Acquisition or Disposition of Assets - Form 8-K
PU
2021Merck Completes Acceleron Pharma Acquisition
MT
2021Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
AQ
2021Merck Completes Cash Tender Offer to Purchase Acceleron Pharma at $180/Share
MT
2021ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P Biotechnology Select Industry Inde..
CI
2021ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P TMI Index
CI
2021ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P Global BMI Index
CI
2021ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Composite Index
CI
2021Merck Completes Tender Offer to Acquire Acceleron Pharma Inc
CI
2021Merck Sharp & Dohme Corp. completed the acquisition of Acceleron Pharma Inc. from Avoro..
CI
2021Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's 'Inadequate' Offe..
MT
2021Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer
BU
2021Merck Extends Tender Offer for Acceleron Pharma
MT
2021Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Ten..
BU
2021Acceleron Reports Third Quarter 2021 Financial Results - Form 8-K
PU
2021ACCELERON : Q3 Earnings Snapshot
AQ
2021Acceleron Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months En..
CI
2021Acceleron Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months En..
CI
2021Earnings Flash (XLRN) ACCELERON PHARMA Reports Q3 Loss $-0.95
MT
2021Acceleron Reports Third Quarter 2021 Financial Results
BU
2021SHAREHOLDER ALERT : WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its ..
PR
2021Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension o..
AQ
2021Merck Extends FTC Review Period for Acceleron Buyout
MT
2021Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders
BU
2021Acceleron Pharma Sees Q3 Reblozyl Royalty Revenue at $32 Million Based on Net Sales of ..
MT
2021Acceleron Announces Third Quarter 2021 REBLOZYL« Net Sales
BU
2021Acceleron Pharma Inc. Provides Revenue Guidance for the Third Quarter Ended September 3..
CI
2021MERCK : Bristol-Myers To Shed Acceleron Stake Ahead Of Merck & Co.'s $11.5 Billion Acquisi..
MT
2021ACCELERON PHARMA ALERT : Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender ..
BU
2021MERCK : Acceleron Pharma Shareholder Says Merck & Co.'s Offer Significantly Undervalues Co..
MT
2021SHAREHOLDER ALERT : Monteverde & Associates PC Announces an Investigation of Acceleron Pha..
PR
2021ACCELERON PHARMA : Holocene Advisors says Merck's offer undervalues Acceleron
RE
2021ACCELERON PHARMA : Holocene Advisors says Merck's offer undervalues Acceleron
RE
2021MERCK : Launches Tender Offer to Buy Acceleron Pharma at $180 Per Share
MT
2021ACCELERON PHARMA : Jefferies Starts Acceleron Pharma at Hold With $180 Price Target
MT
2021ACCELERON PHARMA : Raymond James Downgrades Acceleron Pharma to Market Perform From Strong..
MT
2021ACCELERON INVESTOR ALERT BY THE FORM : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
BU
2021SHAREHOLDER INVESTIGATION : Halper Sadeh LLP Investigates XLRN, ADTN, DSPG, KDMN; Sharehol..
PR
2021ACCELERON PHARMA : Oppenheimer Suspends Rating for Acceleron Pharma, $160 Price Target on ..
MT
2021ACCELERON PHARMA : Morgan Stanley Downgrades Acceleron Pharma to Equalweight from Overweig..
MT
2021ACCELERON PHARMA : Barclays Downgrades Acceleron Pharma to Equal-Weight Rating From Overwe..
MT
2021WALL STREET STOCK EXCHANGE : Autumn cold snap
2021ACCELERON PHARMA : Cowen Downgrades Acceleron Pharma to Market Perform from Outperform, Bo..
MT
2021ANALYST RECOMMENDATIONS : Acceleron Pharma, General Mills, Southwest Airlines, Home Depot,..
2021NORTH AMERICAN MORNING BRIEFING : Fears Heighten -2-
DJ
2021MERCK : to Buy Rare Disease Specialist Acceleron for $11.5 Billion
MT
2021Merck to buy Acceleron for about $11.5 billion in rare disease drug push
RE
2021Health Care Down, But Not By Much, As Deal Activity Cushions Losses - Health Care Round..
DJ
2021Avoro Capital Discloses its Views on Proposed Acquisition of Acceleron Pharma to Merck ..
CI
2021ACCELERON PHARMA : Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merc..
BU
2021Health Care Stocks Closing Slightly Lower After Early Gains
MT
2021ACCELERON MERGER INVESTIGATION : Halper Sadeh LLP Announces Investigation Into Whether the..
BU
2021Health Care Stocks Unable to Sustain Early Rise
MT
2021ACCELERON PHARMA : HC Wainwright Downgrades Acceleron Pharma to Neutral Rating From Buy, A..
MT
2021ACCELERON PHARMA : RBC Capital Again Raises Price Target for Acceleron Pharma to $180 From..
MT
2021ACCELERON PHARMA : SVB Leerink Adjusts Acceleron Pharma PT to $180 from $148, Keeps Market..
MT
2021ACCELERON PHARMA : Piper Sandler Downgrades Acceleron Pharma to Neutral from Overweight, A..
MT
2021SHAREHOLDER ALERT : Ademi LLP investigates whether Acceleron Pharma Inc. has obtained a Fa..
PR
2021WALL STREET STOCK EXCHANGE : Markets take a breather after the purge
2021MERCK : to Buy Acceleron for $11.5 Billion, or $180 Per Share in Cash, to Expand Cardiovas..
MT
2021ACCELERON PHARMA : Merck spends $11.5B for Acceleron, possible blockbuster drug
AQ
2021Health Care Stocks Gain Premarket Thursday
MT
2021ACCELERON PHARMA : REBLOZYL« (luspatercept-aamt) is a First-In-Class Erythroid Maturation ..
PU
2021Merck to Buy Acceleron Pharma for $11.5 Billion
DJ
2021MERCK : to Acquire Acceleron Pharma in $11.5 Billion Deal
MT
2021Merck Sharp & Dohme Corp. ("MSD") entered into a definitive agreement to acquire Accele..
CI
2021GLOBAL MARKETS LIVE : Airbus, Merck, Geely, Toyota, Activision Blizzard...
2021WALL STREET STOCK EXCHANGE : Is inflation still transitionary?
2021NORTH AMERICAN MORNING BRIEFING : Stock Futures Slip as Bond Yields Hit Three-Month High
DJ
2021MERCK : Reportedly in Advanced Talks to Buy Acceleron Pharma
MT
2021MERCK : Said to Buy Acceleron Pharma in Rare Diseases Boost
MT
2021ACCELERON PHARMA : Merck in advanced talks to buy Acceleron Pharma - WSJ
RE
1  2  3  4  5  6  7  8  9Next